Literature DB >> 1398231

Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance.

M H Giaffer1, A Clark, C D Holdsworth.   

Abstract

Saccharomyces cerevisiae (baker's yeast) may play an important part in the pathogenesis of Crohn's disease. Because of this the levels of IgG and IgA antibodies against three S cerevisiae strains (NCYC 77, NCYC 79, and NCYC 1108) were assayed in 49 patients with Crohn's disease, 43 with ulcerative colitis, 14 with coeliac disease, and 21 healthy controls. Coded serum samples were tested by ELISA. Similar antibody patterns to all three strains were found. IgG and IgA antibody levels were significantly raised in patients with Crohn's disease compared with healthy controls (p < 0.001 and p < 0.0001 respectively) and with ulcerative colitis patients (p < 0.0001 and p < 0.0006 respectively). Raised IgA, but not IgG, yeast antibody levels were found in two patients with Crohn's disease who were intolerant to yeast, but these values were similar to those in other patients without yeast intolerance. In ulcerative colitis, both IgG and IgA levels were similar to normal controls. Patients with small bowel Crohn's disease had significantly higher IgG antibody levels than those with colonic disease (p < 0.01). High levels of IgG, but not IgA, antibody were present in patients with coeliac disease, the antibody responses being indistinguishable from those found in Crohn's disease. It is concluded that the presence of IgG antibody to S cerevisiae is characteristic but not specific to Crohn's disease. Although raised IgA antibody levels are more frequently found in Crohn's disease, their pathogenic importance remains to be established.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1398231      PMCID: PMC1379444          DOI: 10.1136/gut.33.8.1071

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease.

Authors:  M H Giaffer; G North; C D Holdsworth
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

2.  Treatment of patient with severe steroid-dependent Crohn's disease with nonelemental formula diet. Identification of possible etiologic dietary factor.

Authors:  A L Ginsberg; M B Albert
Journal:  Dig Dis Sci       Date:  1989-10       Impact factor: 3.199

3.  Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease?

Authors:  R M Barnes; S Allan; C H Taylor-Robinson; R Finn; P M Johnson
Journal:  Int Arch Allergy Appl Immunol       Date:  1990

4.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

5.  Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease. Characterization of the antibody response.

Authors:  K R Falchuk; K J Isselbacher
Journal:  Gastroenterology       Date:  1976-01       Impact factor: 22.682

6.  Antibodies to Eubacterium and Peptostreptococcus species and the estimated probability of Crohn's disease.

Authors:  J P Van de Merwe; P I Schmitz; F Wensinck
Journal:  J Hyg (Lond)       Date:  1981-08

7.  Serum antibodies to cow's milk proteins in ulcerative colitis and Crohn's disease.

Authors:  P Knoflach; B H Park; R Cunningham; M M Weiser; B Albini
Journal:  Gastroenterology       Date:  1987-02       Impact factor: 22.682

8.  Immunoglobulins and dietary protein antibodies in childhood coeliac disease.

Authors:  K G Kenrick; J A Walker-Smith
Journal:  Gut       Date:  1970-08       Impact factor: 23.059

9.  Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease.

Authors:  J Main; H McKenzie; G R Yeaman; M A Kerr; D Robson; C R Pennington; D Parratt
Journal:  BMJ       Date:  1988-10-29

10.  Treatment of Crohn's disease with an unrefined-carbohydrate, fibre-rich diet.

Authors:  K W Heaton; J R Thornton; P M Emmett
Journal:  Br Med J       Date:  1979-09-29
View more
  17 in total

1.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

2.  Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype.

Authors:  Hiromasa Takaishi; Takanori Kanai; Atsushi Nakazawa; Fumihiko Sugata; Akira Nikai; Shigeo Yoshizawa; Yasuo Hamamoto; Shinsuke Funakoshi; Tomoharu Yajima; Yasushi Iwao; Masao Takemura; Shoichi Ozaki; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-05-30       Impact factor: 7.527

3.  ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen?

Authors:  F Seibold
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

4.  Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis.

Authors:  Stefan Müller; Maya Styner; Beatrice Seibold-Schmid; Beatrice Flogerzi; Michael Mähler; Astrid Konrad; Frank Seibold
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

5.  Cytokeratin 18 is an M-cell marker in porcine Peyer's patches.

Authors:  A Gebert; H J Rothkötter; R Pabst
Journal:  Cell Tissue Res       Date:  1994-05       Impact factor: 5.249

6.  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.

Authors:  J F Quinton; B Sendid; D Reumaux; P Duthilleul; A Cortot; B Grandbastien; G Charrier; S R Targan; J F Colombel; D Poulain
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

7.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease.

Authors:  Jan G M C Damoiseaux; Bas Bouten; Annick M L W Linders; Jos Austen; Caroline Roozendaal; Maurice G V M Russel; Pierre-Philippe Forget; Jan Willem Cohen Tervaert
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

8.  Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.

Authors:  Ali Erkan Duman; Sadettin Hülagü; Altay Çelebi; Uğur Korkmaz; Mahmut Mert Musul; Ömer Şentürk; Göktuğ Şirin; Hasan Yılmaz; Deniz Öğütmen Koç; Gökhan Dindar; Murat Öztürkler; Neslihan Bozkurt; Hale Maral Kır
Journal:  Turk J Gastroenterol       Date:  2019-01       Impact factor: 1.852

Review 9.  Current understanding of fungal microflora in inflammatory bowel disease pathogenesis.

Authors:  David Underhill; Jonathan Braun
Journal:  Inflamm Bowel Dis       Date:  2008-08       Impact factor: 5.325

10.  Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease.

Authors:  Zsolt Barta; István Csípõ; Gábor G Szabó; Gyula Szegedi
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.